Gilead Sciences (GILD) Share-based Compensation (2009 - 2026)
Gilead Sciences' (GILD) quarterly Share-based Compensation came in at $218.0 million in Q1 2026, up 4.31% YoY from $209.0 million in Q1 2025, and down 5.22% on a QoQ basis from $230.0 million in Q4 2025.
Gilead Sciences (GILD) Share-based Compensation (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Share-based Compensation data on file, last reported at $218.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 4.31% year-over-year to $218.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $903.0 million (up 5.37% YoY) and the FY2025 annual result came in at $894.0 million, up 7.07% from the prior year.
- Share-based Compensation eased to $218.0 million in Q1 2026, from $230.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $230.0 million in Q3 2025 to a low of $130.0 million in Q1 2022.
- A 5-year average of $197.1 million and a median of $202.0 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slipped 6.47% — and 2023, when it increased 26.92%.
- Tracing GILD's Share-based Compensation over 5 years: stood at $174.0 million in 2022, then grew by 15.52% to $201.0 million in 2023, then increased by 10.45% to $222.0 million in 2024, then increased by 3.6% to $230.0 million in 2025, then dropped by 5.22% to $218.0 million in 2026.
- The last three Share-based Compensation figures came in at $218.0 million (Q1 2026), $230.0 million (Q4 2025), and $230.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 458.00 Mn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | - |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 165.00 Mn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 231.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 231.00 Mn |
| Jun 30, 2026 | 231.00 Mn |
| Mar 31, 2026 | 218.00 Mn |
| Mar 31, 2026 | 218.00 Mn |
| Dec 31, 2025 | 230.00 Mn |
| Dec 31, 2025 | 230.00 Mn |
| Sep 30, 2025 | 230.00 Mn |
| Sep 30, 2025 | 230.00 Mn |
| Jun 30, 2025 | 225.00 Mn |
| Jun 30, 2025 | 225.00 Mn |
| Mar 31, 2025 | 209.00 Mn |
| Mar 31, 2025 | 209.00 Mn |
| Dec 31, 2024 | 222.00 Mn |
| Dec 31, 2024 | 222.00 Mn |
| Sep 30, 2024 | 216.00 Mn |
| Sep 30, 2024 | 216.00 Mn |
| Jun 30, 2024 | 210.00 Mn |
| Jun 30, 2024 | 210.00 Mn |
| Mar 31, 2024 | 187.00 Mn |
| Mar 31, 2024 | 187.00 Mn |